TB-500 (Thymosin Beta-4): An Actin-Sequestering Peptide in Tissue Repair and Regeneration Research

Overview

TB-500 (CAS 77591-33-4) is a synthetic analogue of Thymosin Beta-4 (Tβ4), a 43-amino acid peptide that is one of the most abundant proteins in mammalian cells. Tβ4 was originally isolated from bovine thymus tissue and is now known to be present in virtually all cell types and tissues. TB-500 corresponds to the active region of Tβ4 and shares its primary biological activities.

With a molecular weight of approximately 4,963 Da, TB-500 has the amino acid sequence Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser. Its primary molecular function is the sequestration of G-actin (globular actin), which regulates the polymerization of actin into F-actin (filamentous actin) and controls cell motility, shape, and division.

Mechanism of Action

TB-500's primary mechanism involves binding to G-actin through its LKKTET motif, which is the minimal active sequence required for actin binding and many of the peptide's biological activities. By sequestering G-actin, TB-500 regulates the balance between monomeric and filamentous actin, influencing cell migration, proliferation, and differentiation.

Beyond actin dynamics, TB-500 activates multiple signaling pathways relevant to tissue repair. It promotes the upregulation of cell surface receptors and integrins, enhances the migration of keratinocytes and endothelial cells into wound sites, and stimulates angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and its receptors. TB-500 also has anti-inflammatory properties, reducing the production of pro-inflammatory cytokines and modulating macrophage activity.

In cardiac research, TB-500 has been shown to activate cardiac progenitor cells and stimulate cardiomyocyte survival pathways, with potential relevance to cardiac repair following ischemic injury.

Key Research Findings

Research in wound healing models has demonstrated that TB-500 accelerates wound closure, increases collagen deposition, and improves the quality of healed tissue. Studies in corneal wound models showed that TB-500 significantly accelerated epithelial healing and reduced inflammation. Dermal wound studies in animals demonstrated faster wound closure and increased tensile strength of healed tissue compared to controls.

In cardiac research, studies by Philipp and colleagues demonstrated that TB-500 administration following myocardial infarction in mice reduced infarct size, improved cardiac function, and promoted the migration of cardiac progenitor cells to the site of injury. These findings have generated interest in TB-500 as a potential cardiac repair agent.

Research in musculoskeletal models has explored TB-500's effects on tendon, ligament, and muscle repair. Studies have reported accelerated healing of tendon injuries and reduced fibrosis in muscle injury models, attributed to TB-500's effects on cell migration and extracellular matrix remodeling.

Chemical Properties

| Property | Value | |---|---| | Full Sequence | 43 amino acids (Tβ4 sequence) | | Molecular Weight | ~4,963 Da | | CAS Number | 77591-33-4 | | Active Motif | LKKTET | | Form | Lyophilized powder | | Purity (research grade) | ≥99% HPLC | | Storage | −20°C, protect from light |

Research Considerations

TB-500 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. The peptide is stable in solution for several weeks when stored at 2–8°C. Research protocols should account for TB-500's effects on cell migration and angiogenesis when designing studies, as these properties may influence outcomes in vascular and wound healing models.

Research Use Only. This article is for scientific and educational reference. All products are sold for research purposes only and are not intended for human or animal consumption.